Literature DB >> 32495881

GBP1 promotes non-small cell lung carcinoma malignancy and chemoresistance via activating the Wnt/β-catenin signaling pathway.

J Song1, Q-Y Wei.   

Abstract

OBJECTIVE: Non-small cell lung cancer (NSCLC) is one of the most ordinary cancers worldwide. Recent studies have discovered many oncogenes play vital roles in the tumorigenesis of malignant tumors. The purpose of our study was to uncover the role of GBP1 in NSCLC and the underlying mechanism. PATIENTS AND METHODS: GBP1 expression in NSCLC samples was detected by Real Time quantitative-Polymerase Chain Reaction (RT-qPCR). Function assays were performed in NSCLC cells transfected with GBP1 shRNA. Furthermore, RT-qPCR and Western blot assay were conducted to explore the target signaling pathway of GBP1.
RESULTS: GBP1 expression was significantly upregulated in NSCLC tissue samples compared with adjacent normal tissues. Function assays showed that the proliferation of NSCLC cells was significantly inhibited via knockdown of GBP1, while cell apoptosis was promoted. Resistance to paclitaxel was reversed after GBP1 knockdown in paclitaxel resistance A549 cells (A549/Taxol). In addition, Wnt/β-catenin signaling pathway was repressed via knockdown of GBP1 in NSCLC cells and A549/Taxol cells.
CONCLUSIONS: In our study, GBP1 was firstly identified as a novel oncogene in NSCLC. Furthermore, it could promote NSCLC development and paclitaxel resistance by inducing Wnt/β-catenin signaling pathway.

Entities:  

Year:  2020        PMID: 32495881     DOI: 10.26355/eurrev_202005_21331

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  1 in total

1.  Effect and Mechanism of Transthyretin over-Expression on Proliferation and Cell Cycle of Lung Cancer A549 Cells.

Authors:  Deqing Zhu; Xuan Li; Hao Gong; Jing Li; Xike Lu; Honggang Xia; Xia Chen; Lan Ma; Zhongyi Sun; Xun Zhang; Dongbin Wang
Journal:  Iran J Public Health       Date:  2021-04       Impact factor: 1.429

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.